US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

NanoViricides

1.50

+0.05003.45%

Post-market: 1.530.0300+2.00%19:21 EDT

Volume:584.62K

Turnover:892.09K

Market Cap:26.15M

PE:-2.40

High:1.63

Open:1.47

Low:1.45

Close:1.45

52wk High:1.92

52wk Low:0.9400

Shares:17.43M

Float Shares:16.86M

Volume Ratio:3.27

T/O Rate:3.47%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.6263

EPS(LYR):-0.6263

ROE:-99.75%

ROA:-55.39%

PB:3.48

PE(LYR):-2.40

Loading ...

Overview Company News Filings

NanoViricides Inc. Announces Date for Upcoming Annual Meeting of Stockholders

NanoViricides Inc. Announces New Compensation Agreements, Extends President Dr. Anil Diwan’s Contract with $400,000 Salary and Equity Incentives

Nanoviricides Q4 EPS $(0.13) Up From $(0.19) YoY

NanoViricides Reports No Revenue for Fiscal Year Ended June 30, 2025; Net Loss Continues as R&D Expenses Rise by $112,000

NanoViricides Inc. Announces Phase II Clinical Trial for Broad-Spectrum Antiviral NV-387 Targeting MPOX Disease

NanoViricides Inc. Advances NV-387 into Phase II Clinical Trials for Potential Cancer Resurgence and Viral Infection Treatment

NanoViricides Inc. Announces Promising Results for NV-387 in Combatting Global Measles Outbreaks, Seeks Accelerated FDA Approval

NanoViricides Inc. Announces Breakthrough in Measles Treatment with Successful NV-387 Animal Trials

NanoViricides Inc. Announces Phase II Clinical Trial for NV-387 to Combat MPox Epidemic

NanoViricides Inc. Nears Completion of Phase II Clinical Trial Design for Novel MPox Treatment NV-387

NanoViricides Inc. Announces Phase II Clinical Trial for Broad-Spectrum Antiviral NV-387 Targeting MPox Infection

NanoViricides Inc. Announces Imminent Animal Study for Promising Measles Drug Candidate NV-387

NanoViricides Inc. Announces Phase II Clinical Trial for Broad-Spectrum Antiviral NV-387 to Combat MPox and Measles Outbreaks

Nanoviricides Q3 GAAP EPS $(0.14) Up From $(0.16) YoY

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/NNVC/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NNVC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NNVC\",,,,,undefined,":{"symbol":"NNVC","market":"US","secType":"STK","nameCN":"NanoViricides","latestPrice":1.5,"timestamp":1760731200000,"preClose":1.45,"halted":0,"volume":584620,"hourTrading":{"tag":"盘后","latestPrice":1.53,"preClose":1.5,"latestTime":"19:21 EDT","volume":3211,"amount":4822.0588,"timestamp":1760743306294},"delay":0,"floatShares":16863700,"shares":17431000,"eps":-0.626265,"marketStatus":"Market Closed","change":0.05,"latestTime":"10-17 16:00:00 EDT","open":1.47,"high":1.63,"low":1.45,"amount":892091.0089220001,"amplitude":0.124138,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.626265,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1760947200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1380081600000,"exchange":"AMEX","adjPreClose":1.45,"preHourTrading":{"tag":"盘前","latestPrice":1.4495,"preClose":1.45,"latestTime":"09:28 EDT","volume":4205,"amount":6112.383795000001,"timestamp":1760707715568},"postHourTrading":{"tag":"盘后","latestPrice":1.53,"preClose":1.5,"latestTime":"19:21 EDT","volume":3211,"amount":4822.0588,"timestamp":1760743306294},"volumeRatio":3.2748004716131005,"impliedVol":0.4743,"impliedVolPercentile":0.192},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NNVC\",,,,,undefined,":{"symbol":"NNVC","floatShares":16863700,"roa":"-55.39%","roe":"-99.75%","lyrEps":-0.626265,"volumeRatio":3.2748004716131005,"shares":17431000,"dividePrice":0,"high":1.63,"amplitude":0.124138,"preClose":1.45,"low":1.45,"week52Low":0.94,"pbRate":"3.48","week52High":1.9195,"institutionHeld":0,"latestPrice":1.5,"eps":-0.626265,"divideRate":0,"volume":584620,"delay":0,"ttmEps":-0.626265,"open":1.47,"prevYearClose":1.43,"prevWeekClose":1.37,"prevMonthClose":1.43,"prevQuarterClose":1.43,"fiveDayClose":1.37,"twentyDayClose":1.47,"sixtyDayClose":1.71},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NNVC\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-09-29","symbol":"NNVC","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1759118400000,"reportTimeType":"post","actualEps":-0.13},{"market":"US","date":"2025-05-15","symbol":"NNVC","fiscalQuarterEnding":"2025/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"post","actualEps":-0.14},{"market":"US","date":"2025-02-14","symbol":"NNVC","fiscalQuarterEnding":"2024/12","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1739509200000,"reportTimeType":"post","actualEps":-0.14},{"market":"US","date":"2024-11-14","symbol":"NNVC","fiscalQuarterEnding":"2024/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"post","actualEps":-0.23},{"market":"US","date":"2024-09-27","symbol":"NNVC","fiscalQuarterEnding":"2024/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1727409600000,"reportTimeType":"post","actualEps":-0.19}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NNVC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NNVC\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NNVC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NNVC","date":"2025-10-17","current":-2.395152,"percent":0.360791,"low":-8.257983,"twenty":-3.208752,"median":-2.395993,"eighty":-2.020561,"high":-1.333135,"avg":-2.810691,"sd":1.25075,"marketCap":25274950},"quantilePoints":[{"date":"2020-10-23","current":-3.088522,"twenty":-11.551315,"median":-5.80821,"eighty":-2.576332,"marketCap":41529926},{"date":"2020-10-30","current":-2.731323,"twenty":-11.551315,"median":-5.763677,"eighty":-2.576332,"marketCap":36726837},{"date":"2020-11-06","current":-2.73924,"twenty":-11.551315,"median":-5.704394,"eighty":-2.576332,"marketCap":36833291},{"date":"2020-11-13","current":-2.778824,"twenty":-11.551315,"median":-5.646071,"eighty":-2.576332,"marketCap":37365564},{"date":"2020-11-20","current":-2.817128,"twenty":-11.551315,"median":-5.55316,"eighty":-2.576332,"marketCap":39993750},{"date":"2020-11-27","current":-2.704443,"twenty":-11.551315,"median":-5.550142,"eighty":-2.576332,"marketCap":38394000},{"date":"2020-12-04","current":-2.907276,"twenty":-11.551315,"median":-5.479283,"eighty":-2.576332,"marketCap":41273550},{"date":"2020-12-11","current":-2.606783,"twenty":-11.551315,"median":-5.436362,"eighty":-2.576332,"marketCap":37007550},{"date":"2020-12-18","current":-2.636832,"twenty":-11.551315,"median":-5.410581,"eighty":-2.576332,"marketCap":37434150},{"date":"2020-12-24","current":-2.636832,"twenty":-11.551315,"median":-5.369111,"eighty":-2.576332,"marketCap":37434150},{"date":"2020-12-31","current":-2.156042,"twenty":-11.481307,"median":-5.329042,"eighty":-2.551389,"marketCap":30608550},{"date":"2021-01-08","current":-2.464048,"twenty":-11.481307,"median":-5.269538,"eighty":-2.537233,"marketCap":34981200},{"date":"2021-01-15","current":-2.464048,"twenty":-11.481307,"median":-5.232807,"eighty":-2.519791,"marketCap":34981200},{"date":"2021-01-22","current":-3.327968,"twenty":-11.481307,"median":-5.222018,"eighty":-2.519791,"marketCap":47245950},{"date":"2021-01-29","current":-3.034986,"twenty":-11.481307,"median":-5.155523,"eighty":-2.519791,"marketCap":43086600},{"date":"2021-02-05","current":-3.538313,"twenty":-11.4113,"median":-5.109511,"eighty":-2.519791,"marketCap":50232150},{"date":"2021-02-12","current":-3.78622,"twenty":-11.341292,"median":-5.07155,"eighty":-2.519791,"marketCap":53751600},{"date":"2021-02-19","current":-3.620149,"twenty":-11.311529,"median":-5.024525,"eighty":-2.519791,"marketCap":52851150},{"date":"2021-02-26","current":-3.057014,"twenty":-11.271284,"median":-5.00388,"eighty":-2.519791,"marketCap":44629860},{"date":"2021-03-05","current":-3.876119,"twenty":-11.177066,"median":-4.973773,"eighty":-2.518657,"marketCap":56588100},{"date":"2021-03-12","current":-3.817611,"twenty":-11.075262,"median":-4.952574,"eighty":-2.518657,"marketCap":55733940},{"date":"2021-03-19","current":-3.678656,"twenty":-10.947439,"median":-4.928766,"eighty":-2.518657,"marketCap":53705310},{"date":"2021-03-26","current":-3.605522,"twenty":-10.921244,"median":-4.89353,"eighty":-2.519791,"marketCap":52637610},{"date":"2021-04-01","current":-3.47388,"twenty":-10.851236,"median":-4.872521,"eighty":-2.519791,"marketCap":50715750},{"date":"2021-04-09","current":-3.408059,"twenty":-10.781228,"median":-4.831249,"eighty":-2.518657,"marketCap":49754820},{"date":"2021-04-16","current":-3.00582,"twenty":-10.596948,"median":-4.785979,"eighty":-2.518657,"marketCap":43882470},{"date":"2021-04-23","current":-3.057014,"twenty":-10.508695,"median":-4.726099,"eighty":-2.518657,"marketCap":44629860},{"date":"2021-04-30","current":-3.035074,"twenty":-10.404778,"median":-4.666105,"eighty":-2.518657,"marketCap":44309550},{"date":"2021-05-07","current":-2.654776,"twenty":-9.700722,"median":-4.544321,"eighty":-2.518657,"marketCap":38757510},{"date":"2021-05-14","current":-4.562569,"twenty":-9.419194,"median":-4.510132,"eighty":-2.506117,"marketCap":39347100},{"date":"2021-05-21","current":-4.776022,"twenty":-9.231528,"median":-4.510132,"eighty":-2.506117,"marketCap":41187900},{"date":"2021-05-28","current":-4.789363,"twenty":-9.074029,"median":-4.510132,"eighty":-2.506117,"marketCap":41302950},{"date":"2021-06-04","current":-5.002817,"twenty":-9.026854,"median":-4.518582,"eighty":-2.509122,"marketCap":43143750},{"date":"2021-06-11","current":-5.883312,"twenty":-8.963729,"median":-4.518582,"eighty":-2.509122,"marketCap":50737050},{"date":"2021-06-18","current":-5.082862,"twenty":-8.899973,"median":-4.518582,"eighty":-2.509122,"marketCap":43834050},{"date":"2021-06-25","current":-6.216833,"twenty":-8.83748,"median":-4.518582,"eighty":-2.509122,"marketCap":53613300},{"date":"2021-07-02","current":-5.736563,"twenty":-8.774355,"median":-4.518582,"eighty":-2.509122,"marketCap":49471500},{"date":"2021-07-09","current":-5.576473,"twenty":-8.71123,"median":-4.518582,"eighty":-2.509122,"marketCap":48090900},{"date":"2021-07-16","current":-5.242952,"twenty":-8.71123,"median":-4.518582,"eighty":-2.509122,"marketCap":45214650},{"date":"2021-07-23","current":-5.656518,"twenty":-8.672078,"median":-4.518582,"eighty":-2.509122,"marketCap":48781200},{"date":"2021-07-30","current":-5.363019,"twenty":-8.648105,"median":-4.518582,"eighty":-2.509122,"marketCap":46250100},{"date":"2021-08-06","current":-5.21627,"twenty":-8.605807,"median":-4.518582,"eighty":-2.509122,"marketCap":44984550},{"date":"2021-08-13","current":-5.069521,"twenty":-8.58498,"median":-4.518582,"eighty":-2.509122,"marketCap":43719000},{"date":"2021-08-20","current":-4.949453,"twenty":-8.521855,"median":-4.518582,"eighty":-2.509122,"marketCap":42683550},{"date":"2021-08-27","current":-5.136225,"twenty":-8.381184,"median":-4.527033,"eighty":-2.509122,"marketCap":44294250},{"date":"2021-09-03","current":-5.363019,"twenty":-8.332481,"median":-4.527335,"eighty":-2.509122,"marketCap":46250100},{"date":"2021-09-10","current":-5.256293,"twenty":-8.269356,"median":-4.527335,"eighty":-2.509122,"marketCap":45329700},{"date":"2021-09-17","current":-5.363019,"twenty":-8.206231,"median":-4.527335,"eighty":-2.509122,"marketCap":46250100},{"date":"2021-09-24","current":-6.777149,"twenty":-8.180981,"median":-4.527335,"eighty":-2.509122,"marketCap":58445400},{"date":"2021-10-01","current":-5.869971,"twenty":-8.079981,"median":-4.527335,"eighty":-2.509122,"marketCap":50622000},{"date":"2021-10-08","current":-5.829949,"twenty":-8.016857,"median":-4.527335,"eighty":-2.509122,"marketCap":50276850},{"date":"2021-10-15","current":-6.36953,"twenty":-8.010675,"median":-4.527335,"eighty":-2.509122,"marketCap":56193200},{"date":"2021-10-22","current":-6.304269,"twenty":-7.953732,"median":-4.527335,"eighty":-2.509122,"marketCap":55617450},{"date":"2021-10-29","current":-6.186798,"twenty":-7.94329,"median":-4.527335,"eighty":-2.509122,"marketCap":54581100},{"date":"2021-11-05","current":-6.173746,"twenty":-7.890607,"median":-4.527335,"eighty":-2.509122,"marketCap":54465950},{"date":"2021-11-12","current":-6.095432,"twenty":-7.788302,"median":-4.527335,"eighty":-2.509122,"marketCap":53775050},{"date":"2021-11-19","current":-5.797853,"twenty":-7.663997,"median":-4.527335,"eighty":-2.509122,"marketCap":52899750},{"date":"2021-11-26","current":-6.138903,"twenty":-7.585674,"median":-4.527335,"eighty":-2.509122,"marketCap":56011500},{"date":"2021-12-03","current":-5.633644,"twenty":-7.428051,"median":-4.527335,"eighty":-2.509122,"marketCap":51401500},{"date":"2021-12-10","current":-5.406277,"twenty":-7.300703,"median":-4.527335,"eighty":-2.509122,"marketCap":49327000},{"date":"2021-12-17","current":-5.229436,"twenty":-7.180968,"median":-4.527335,"eighty":-2.509122,"marketCap":47713500},{"date":"2021-12-23","current":-4.976806,"twenty":-7.079181,"median":-4.527335,"eighty":-2.509122,"marketCap":45408500},{"date":"2021-12-31","current":-4.698914,"twenty":-6.987904,"median":-4.527335,"eighty":-2.509122,"marketCap":42873000},{"date":"2022-01-07","current":-3.890498,"twenty":-6.926651,"median":-4.436412,"eighty":-2.509122,"marketCap":35497000},{"date":"2022-01-14","current":-3.675763,"twenty":-6.89782,"median":-4.401483,"eighty":-2.509122,"marketCap":33537750},{"date":"2022-01-21","current":-2.905242,"twenty":-6.846702,"median":-4.310739,"eighty":-2.509122,"marketCap":26507500},{"date":"2022-01-28","current":-2.728401,"twenty":-6.779582,"median":-4.173405,"eighty":-2.509122,"marketCap":24894000},{"date":"2022-02-04","current":-3.05682,"twenty":-6.712109,"median":-4.02803,"eighty":-2.509122,"marketCap":27890500},{"date":"2022-02-11","current":-2.854716,"twenty":-6.637806,"median":-3.995999,"eighty":-2.509122,"marketCap":26046500},{"date":"2022-02-18","current":-2.62043,"twenty":-6.580578,"median":-3.946834,"eighty":-2.509122,"marketCap":22837320},{"date":"2022-02-25","current":-2.646899,"twenty":-6.52606,"median":-3.923893,"eighty":-2.509122,"marketCap":23068000},{"date":"2022-03-04","current":-2.50132,"twenty":-6.496806,"median":-3.868397,"eighty":-2.507562,"marketCap":21799260},{"date":"2022-03-11","current":-2.448382,"twenty":-6.462701,"median":-3.821268,"eighty":-2.492597,"marketCap":21337900},{"date":"2022-03-18","current":-2.964527,"twenty":-6.435992,"median":-3.787617,"eighty":-2.484025,"marketCap":25836160},{"date":"2022-03-25","current":-3.096872,"twenty":-6.399341,"median":-3.766488,"eighty":-2.484025,"marketCap":26989560},{"date":"2022-04-01","current":-2.73954,"twenty":-6.395635,"median":-3.735019,"eighty":-2.484025,"marketCap":23875380},{"date":"2022-04-08","current":-2.593961,"twenty":-6.356646,"median":-3.703835,"eighty":-2.484025,"marketCap":22606640},{"date":"2022-04-14","current":-2.501584,"twenty":-6.335311,"median":-3.656716,"eighty":-2.482663,"marketCap":21801566},{"date":"2022-04-22","current":-2.223395,"twenty":-6.304269,"median":-3.638432,"eighty":-2.478152,"marketCap":19377120},{"date":"2022-04-29","current":-1.97194,"twenty":-6.279718,"median":-3.579246,"eighty":-2.47116,"marketCap":17185660},{"date":"2022-05-06","current":-1.97194,"twenty":-6.219501,"median":-3.523708,"eighty":-2.460477,"marketCap":17185660},{"date":"2022-05-13","current":-1.710426,"twenty":-6.176384,"median":-3.477537,"eighty":-2.45259,"marketCap":14906541},{"date":"2022-05-20","current":-3.57635,"twenty":-6.112925,"median":-3.448283,"eighty":-2.44683,"marketCap":30040400},{"date":"2022-05-27","current":-2.957366,"twenty":-6.0948,"median":-3.404402,"eighty":-2.44683,"marketCap":24841100},{"date":"2022-06-03","current":-2.751038,"twenty":-6.063146,"median":-3.382022,"eighty":-2.44683,"marketCap":23108000},{"date":"2022-06-10","current":-2.778549,"twenty":-6.021887,"median":-3.36235,"eighty":-2.44683,"marketCap":23339080},{"date":"2022-06-17","current":-2.764793,"twenty":-5.978029,"median":-3.327968,"eighty":-2.44683,"marketCap":23223540},{"date":"2022-06-24","current":-2.806059,"twenty":-5.953332,"median":-3.30945,"eighty":-2.445278,"marketCap":23570160},{"date":"2022-07-01","current":-2.599731,"twenty":-5.898451,"median":-3.23985,"eighty":-2.445278,"marketCap":21837060},{"date":"2022-07-08","current":-3.148563,"twenty":-5.871439,"median":-3.219656,"eighty":-2.445278,"marketCap":26447106},{"date":"2022-07-15","current":-2.737283,"twenty":-5.837732,"median":-3.192745,"eighty":-2.445278,"marketCap":22992460},{"date":"2022-07-22","current":-2.874835,"twenty":-5.807263,"median":-3.167389,"eighty":-2.445278,"marketCap":24147860},{"date":"2022-07-29","current":-2.503445,"twenty":-5.78537,"median":-3.144776,"eighty":-2.440257,"marketCap":21028280},{"date":"2022-08-05","current":-4.869338,"twenty":-5.744619,"median":-3.132647,"eighty":-2.440257,"marketCap":40901160},{"date":"2022-08-12","current":-3.823943,"twenty":-5.727928,"median":-3.132647,"eighty":-2.440257,"marketCap":32120120},{"date":"2022-08-19","current":-3.342511,"twenty":-5.684312,"median":-3.132647,"eighty":-2.440257,"marketCap":28076220},{"date":"2022-08-26","current":-3.094918,"twenty":-5.661854,"median":-3.132245,"eighty":-2.440257,"marketCap":25996500},{"date":"2022-09-02","current":-2.902345,"twenty":-5.581809,"median":-3.128118,"eighty":-2.440257,"marketCap":24378940},{"date":"2022-09-09","current":-2.984876,"twenty":-5.560806,"median":-3.117013,"eighty":-2.440257,"marketCap":25072180},{"date":"2022-09-16","current":-2.668507,"twenty":-5.55316,"median":-3.10436,"eighty":-2.440257,"marketCap":22414760},{"date":"2022-09-23","current":-2.14581,"twenty":-5.519162,"median":-3.095823,"eighty":-2.439684,"marketCap":18024240},{"date":"2022-09-30","current":-2.379648,"twenty":-5.477266,"median":-3.088522,"eighty":-2.439647,"marketCap":19988420},{"date":"2022-10-07","current":-2.132055,"twenty":-5.456405,"median":-3.080603,"eighty":-2.439647,"marketCap":17908700},{"date":"2022-10-14","current":-2.502362,"twenty":-5.43594,"median":-3.072683,"eighty":-2.437394,"marketCap":20286302},{"date":"2022-10-21","current":-2.402267,"twenty":-5.421719,"median":-3.06696,"eighty":-2.434784,"marketCap":19474850},{"date":"2022-10-28","current":-2.359369,"twenty":-5.377446,"median":-3.06013,"eighty":-2.430342,"marketCap":19127085},{"date":"2022-11-04","current":-2.334363,"twenty":-5.363019,"median":-3.057014,"eighty":-2.4206,"marketCap":18924360},{"date":"2022-11-11","current":-2.477575,"twenty":-5.336338,"median":-3.043934,"eighty":-2.417533,"marketCap":20085364},{"date":"2022-11-18","current":-2.711681,"twenty":-5.332826,"median":-3.036058,"eighty":-2.417533,"marketCap":19156500},{"date":"2022-11-25","current":-2.760984,"twenty":-5.332826,"median":-3.034986,"eighty":-2.417533,"marketCap":19504800},{"date":"2022-12-02","current":-2.777419,"twenty":-5.332826,"median":-3.028333,"eighty":-2.417533,"marketCap":19620900},{"date":"2022-12-09","current":-2.39121,"twenty":-5.292381,"median":-3.026142,"eighty":-2.416192,"marketCap":16892550},{"date":"2022-12-16","current":-2.087173,"twenty":-5.292381,"median":-3.018926,"eighty":-2.406742,"marketCap":14744700},{"date":"2022-12-23","current":-1.972132,"twenty":-5.292381,"median":-3.00582,"eighty":-2.395506,"marketCap":13932000},{"date":"2022-12-30","current":-1.824222,"twenty":-5.292381,"median":-2.997432,"eighty":-2.389879,"marketCap":12887100},{"date":"2023-01-06","current":-2.202214,"twenty":-5.277173,"median":-2.989706,"eighty":-2.387968,"marketCap":15557400},{"date":"2023-01-13","current":-2.333853,"twenty":-5.260084,"median":-2.981981,"eighty":-2.376115,"marketCap":16487361},{"date":"2023-01-20","current":-2.30082,"twenty":-5.250996,"median":-2.973783,"eighty":-2.373517,"marketCap":16254000},{"date":"2023-01-27","current":-2.399427,"twenty":-5.240028,"median":-2.96653,"eighty":-2.370947,"marketCap":16950600},{"date":"2023-02-03","current":-2.284386,"twenty":-5.221675,"median":-2.956693,"eighty":-2.366583,"marketCap":16137900},{"date":"2023-02-10","current":-2.276169,"twenty":-5.202929,"median":-2.950137,"eighty":-2.360695,"marketCap":16079850},{"date":"2023-02-17","current":-2.44914,"twenty":-5.171998,"median":-2.943354,"eighty":-2.359369,"marketCap":16870750},{"date":"2023-02-24","current":-2.128219,"twenty":-5.154465,"median":-2.937326,"eighty":-2.348627,"marketCap":14660100},{"date":"2023-03-03","current":-2.330906,"twenty":-5.122989,"median":-2.92765,"eighty":-2.343232,"marketCap":16056300},{"date":"2023-03-10","current":-2.145109,"twenty":-5.087088,"median":-2.913716,"eighty":-2.342061,"marketCap":14776450},{"date":"2023-03-17","current":-2.195781,"twenty":-5.05618,"median":-2.905242,"eighty":-2.334159,"marketCap":15125500},{"date":"2023-03-24","current":-2.094437,"twenty":-5.017952,"median":-2.902345,"eighty":-2.329408,"marketCap":14427400},{"date":"2023-03-31","current":-1.97975,"twenty":-5.017055,"median":-2.891819,"eighty":-2.325041,"marketCap":13637383},{"date":"2023-04-06","current":-2.753172,"twenty":-5.017055,"median":-2.888698,"eighty":-2.322276,"marketCap":18965050},{"date":"2023-04-14","current":-1.993094,"twenty":-5.017952,"median":-2.874835,"eighty":-2.316037,"marketCap":13729300},{"date":"2023-04-21","current":-2.263344,"twenty":-5.002368,"median":-2.859591,"eighty":-2.313801,"marketCap":15590900},{"date":"2023-04-28","current":-2.280234,"twenty":-5.002368,"median":-2.849614,"eighty":-2.312786,"marketCap":15707250},{"date":"2023-05-05","current":-2.077547,"twenty":-5.002368,"median":-2.840873,"eighty":-2.302937,"marketCap":14311050},{"date":"2023-05-11","current":-2.043766,"twenty":-5.002368,"median":-2.835777,"eighty":-2.30082,"marketCap":14078350},{"date":"2023-05-19","current":-1.920317,"twenty":-5.002518,"median":-2.832097,"eighty":-2.294808,"marketCap":13055420},{"date":"2023-05-26","current":-1.887542,"twenty":-5.002667,"median":-2.817128,"eighty":-2.284962,"marketCap":12832600},{"date":"2023-06-02","current":-2.239311,"twenty":-5.002667,"median":-2.810544,"eighty":-2.283362,"marketCap":15224130},{"date":"2023-06-09","current":-1.973339,"twenty":-5.002817,"median":-2.806059,"eighty":-2.276679,"marketCap":13415900},{"date":"2023-06-16","current":-1.870383,"twenty":-5.008153,"median":-2.792391,"eighty":-2.269675,"marketCap":12715940},{"date":"2023-06-23","current":-1.921861,"twenty":-5.010821,"median":-2.779567,"eighty":-2.263344,"marketCap":13065920},{"date":"2023-06-30","current":-2.144934,"twenty":-5.017055,"median":-2.778549,"eighty":-2.263295,"marketCap":14582500},{"date":"2023-07-06","current":-2.024818,"twenty":-5.017952,"median":-2.777419,"eighty":-2.259272,"marketCap":13765880},{"date":"2023-07-14","current":-2.488124,"twenty":-5.020645,"median":-2.769833,"eighty":-2.254292,"marketCap":16915700},{"date":"2023-07-21","current":-2.745516,"twenty":-5.0361,"median":-2.767019,"eighty":-2.252684,"marketCap":18665600},{"date":"2023-07-27","current":-2.676878,"twenty":-5.039964,"median":-2.764793,"eighty":-2.252282,"marketCap":18198960},{"date":"2023-08-04","current":-2.453805,"twenty":-5.039964,"median":-2.753964,"eighty":-2.252129,"marketCap":16682380},{"date":"2023-08-11","current":-2.219738,"twenty":-5.039964,"median":-2.751307,"eighty":-2.246058,"marketCap":15091061},{"date":"2023-08-18","current":-2.21991,"twenty":-5.039964,"median":-2.751307,"eighty":-2.244476,"marketCap":15092230},{"date":"2023-08-25","current":-2.667127,"twenty":-5.039964,"median":-2.753168,"eighty":-2.251186,"marketCap":18132670},{"date":"2023-09-01","current":-2.495054,"twenty":-5.039964,"median":-2.751038,"eighty":-2.251186,"marketCap":16962820},{"date":"2023-09-08","current":-2.340189,"twenty":-5.039964,"median":-2.74376,"eighty":-2.251186,"marketCap":15909955},{"date":"2023-09-15","current":-2.288567,"twenty":-5.039964,"median":-2.738088,"eighty":-2.246453,"marketCap":15559001},{"date":"2023-09-22","current":-2.185324,"twenty":-5.039964,"median":-2.725967,"eighty":-2.236945,"marketCap":14857091},{"date":"2023-09-29","current":-2.426225,"twenty":-5.039964,"median":-2.723609,"eighty":-2.236573,"marketCap":16494880},{"date":"2023-10-06","current":-2.254153,"twenty":-5.039964,"median":-2.723609,"eighty":-2.234464,"marketCap":15325031},{"date":"2023-10-13","current":-2.013251,"twenty":-5.039964,"median":-2.723467,"eighty":-2.230216,"marketCap":13687241},{"date":"2023-10-20","current":-1.572776,"twenty":-5.039964,"median":-2.723467,"eighty":-2.222732,"marketCap":13507900},{"date":"2023-10-27","current":-1.600128,"twenty":-5.039964,"median":-2.72369,"eighty":-2.219772,"marketCap":13742820},{"date":"2023-11-03","current":-1.5591,"twenty":-5.039964,"median":-2.72369,"eighty":-2.211571,"marketCap":13390440},{"date":"2023-11-10","current":-1.463365,"twenty":-5.039964,"median":-2.718749,"eighty":-2.202243,"marketCap":12568220},{"date":"2023-11-17","current":-1.487026,"twenty":-5.039964,"median":-2.715489,"eighty":-2.195907,"marketCap":13363424},{"date":"2023-11-24","current":-1.359275,"twenty":-5.039964,"median":-2.713071,"eighty":-2.189723,"marketCap":12215368},{"date":"2023-12-01","current":-1.503045,"twenty":-5.039964,"median":-2.709773,"eighty":-2.185324,"marketCap":13507379},{"date":"2023-12-08","current":-1.50958,"twenty":-5.039964,"median":-2.70214,"eighty":-2.168223,"marketCap":13566106},{"date":"2023-12-15","current":-1.489975,"twenty":-5.039964,"median":-2.696474,"eighty":-2.162,"marketCap":13389923},{"date":"2023-12-22","current":-1.385415,"twenty":-5.039964,"median":-2.696474,"eighty":-2.156514,"marketCap":12450279},{"date":"2023-12-29","current":-1.398485,"twenty":-5.039964,"median":-2.696931,"eighty":-2.156278,"marketCap":12567735},{"date":"2024-01-05","current":-1.424625,"twenty":-5.039964,"median":-2.698293,"eighty":-2.150909,"marketCap":12802646},{"date":"2024-01-12","current":-1.353525,"twenty":-5.039964,"median":-2.698293,"eighty":-2.145109,"marketCap":12163688},{"date":"2024-01-19","current":-1.359275,"twenty":-5.043083,"median":-2.699655,"eighty":-2.135592,"marketCap":12215368},{"date":"2024-01-26","current":-1.385415,"twenty":-5.039964,"median":-2.698293,"eighty":-2.120042,"marketCap":12450279},{"date":"2024-02-02","current":-1.476905,"twenty":-5.039964,"median":-2.698293,"eighty":-2.111328,"marketCap":13272468},{"date":"2024-02-09","current":-1.516115,"twenty":-5.039964,"median":-2.687524,"eighty":-2.094437,"marketCap":13624834},{"date":"2024-02-16","current":-1.498107,"twenty":-5.039964,"median":-2.682084,"eighty":-2.081184,"marketCap":14017010},{"date":"2024-02-23","current":-1.59882,"twenty":-5.039964,"median":-2.676392,"eighty":-2.064581,"marketCap":14959330},{"date":"2024-03-01","current":-1.699533,"twenty":-5.0361,"median":-2.668507,"eighty":-2.049674,"marketCap":15901650},{"date":"2024-03-08","current":-1.422572,"twenty":-5.0361,"median":-2.666881,"eighty":-2.03312,"marketCap":13310270},{"date":"2024-03-15","current":-1.472929,"twenty":-5.0361,"median":-2.656354,"eighty":-2.014962,"marketCap":13781430},{"date":"2024-03-22","current":-1.435162,"twenty":-5.0361,"median":-2.651857,"eighty":-1.997134,"marketCap":13428060},{"date":"2024-03-28","current":-1.422572,"twenty":-5.0361,"median":-2.646899,"eighty":-1.988953,"marketCap":13310270},{"date":"2024-04-05","current":-1.724712,"twenty":-5.039964,"median":-2.645782,"eighty":-1.976203,"marketCap":16137230},{"date":"2024-04-12","current":-1.59882,"twenty":-5.039964,"median":-2.640997,"eighty":-1.967997,"marketCap":14959330},{"date":"2024-04-19","current":-1.479223,"twenty":-5.039964,"median":-2.636576,"eighty":-1.942422,"marketCap":13840325},{"date":"2024-04-26","current":-1.397394,"twenty":-5.0361,"median":-2.625126,"eighty":-1.921861,"marketCap":13074690},{"date":"2024-05-03","current":-1.510696,"twenty":-5.0361,"median":-2.62043,"eighty":-1.908491,"marketCap":14134800},{"date":"2024-05-10","current":-2.303812,"twenty":-5.0361,"median":-2.62043,"eighty":-1.904702,"marketCap":21555570},{"date":"2024-05-17","current":-2.762595,"twenty":-5.0361,"median":-2.63632,"eighty":-1.904702,"marketCap":26267170},{"date":"2024-05-24","current":-2.762595,"twenty":-5.0361,"median":-2.640997,"eighty":-1.904702,"marketCap":26267170},{"date":"2024-05-31","current":-3.010361,"twenty":-5.0361,"median":-2.645943,"eighty":-1.904702,"marketCap":28622970},{"date":"2024-06-07","current":-3.282904,"twenty":-5.0361,"median":-2.651857,"eighty":-1.904702,"marketCap":31214350},{"date":"2024-06-14","current":-3.205683,"twenty":-5.039964,"median":-2.663299,"eighty":-1.904702,"marketCap":30480120},{"date":"2024-06-21","current":-2.522301,"twenty":-5.039964,"median":-2.666881,"eighty":-1.904582,"marketCap":23982420},{"date":"2024-06-28","current":-2.149547,"twenty":-5.039964,"median":-2.667004,"eighty":-1.904221,"marketCap":20438220},{"date":"2024-07-05","current":-2.186822,"twenty":-5.039964,"median":-2.667004,"eighty":-1.904221,"marketCap":20792640},{"date":"2024-07-12","current":-2.236523,"twenty":-5.039964,"median":-2.667004,"eighty":-1.904221,"marketCap":21265200},{"date":"2024-07-15","current":-2.161972,"twenty":-5.039964,"median":-2.667004,"eighty":-1.904221,"marketCap":20556360},{"date":"2024-08-02","current":-2.609277,"twenty":-5.05618,"median":-2.674394,"eighty":-1.887542,"marketCap":24809400},{"date":"2024-08-09","current":-2.360774,"twenty":-5.05618,"median":-2.674394,"eighty":-1.887542,"marketCap":22446600},{"date":"2024-08-16","current":-2.360774,"twenty":-5.05618,"median":-2.674394,"eighty":-1.887542,"marketCap":22446600},{"date":"2024-08-23","current":-2.286223,"twenty":-5.05618,"median":-2.675731,"eighty":-1.887542,"marketCap":21737760},{"date":"2024-08-30","current":-2.335924,"twenty":-5.05618,"median":-2.675731,"eighty":-1.890067,"marketCap":22210320},{"date":"2024-09-06","current":-2.224098,"twenty":-5.05618,"median":-2.675731,"eighty":-1.890067,"marketCap":21147060},{"date":"2024-09-13","current":-2.087421,"twenty":-5.05618,"median":-2.675731,"eighty":-1.899521,"marketCap":19847520},{"date":"2024-09-20","current":-1.96317,"twenty":-5.05618,"median":-2.675731,"eighty":-1.917578,"marketCap":18666120},{"date":"2024-09-27","current":-1.764368,"twenty":-5.05618,"median":-2.675731,"eighty":-1.921243,"marketCap":16775880},{"date":"2024-10-04","current":-2.008373,"twenty":-5.05618,"median":-2.675731,"eighty":-1.947416,"marketCap":16657740},{"date":"2024-10-11","current":-1.951398,"twenty":-5.05618,"median":-2.675731,"eighty":-1.961627,"marketCap":16185180},{"date":"2024-10-18","current":-2.122323,"twenty":-5.05618,"median":-2.675731,"eighty":-1.972856,"marketCap":17602860},{"date":"2024-10-25","current":-2.122323,"twenty":-5.05618,"median":-2.675731,"eighty":-1.978331,"marketCap":17602860},{"date":"2024-10-31","current":-1.937154,"twenty":-5.05618,"median":-2.675731,"eighty":-1.988348,"marketCap":16067040},{"date":"2024-11-08","current":-2.122323,"twenty":-5.05618,"median":-2.675818,"eighty":-2.003331,"marketCap":17602860},{"date":"2024-11-15","current":-1.908667,"twenty":-5.05618,"median":-2.675818,"eighty":-2.007658,"marketCap":15830760},{"date":"2024-11-22","current":-1.599829,"twenty":-5.05618,"median":-2.675818,"eighty":-2.007658,"marketCap":15121920},{"date":"2024-11-29","current":-2.06427,"twenty":-5.05618,"median":-2.675818,"eighty":-2.022617,"marketCap":19511920},{"date":"2024-12-06","current":-2.216055,"twenty":-5.05618,"median":-2.675818,"eighty":-2.028308,"marketCap":20946620},{"date":"2024-12-13","current":-2.231234,"twenty":-5.05618,"median":-2.675818,"eighty":-2.043766,"marketCap":21090090},{"date":"2024-12-20","current":-2.200877,"twenty":-5.05618,"median":-2.675818,"eighty":-2.051201,"marketCap":20803150},{"date":"2024-12-27","current":-2.291947,"twenty":-5.05618,"median":-2.675818,"eighty":-2.063251,"marketCap":21663970},{"date":"2025-01-03","current":-2.155341,"twenty":-5.05618,"median":-2.675818,"eighty":-2.067504,"marketCap":20372740},{"date":"2025-01-10","current":-2.109806,"twenty":-5.05618,"median":-2.675905,"eighty":-2.079813,"marketCap":19942330},{"date":"2025-01-17","current":-1.821415,"twenty":-5.05618,"median":-2.675905,"eighty":-2.079813,"marketCap":17216400},{"date":"2025-01-24","current":-1.699987,"twenty":-5.05618,"median":-2.675731,"eighty":-2.077956,"marketCap":16068640},{"date":"2025-01-31","current":-1.624095,"twenty":-5.019747,"median":-2.668507,"eighty":-2.064332,"marketCap":15351290},{"date":"2025-02-07","current":-1.86695,"twenty":-4.974978,"median":-2.666881,"eighty":-2.051347,"marketCap":17646810},{"date":"2025-02-14","current":-1.958021,"twenty":-4.948211,"median":-2.651857,"eighty":-2.049178,"marketCap":18507630},{"date":"2025-02-21","current":-2.42188,"twenty":-4.923399,"median":-2.645943,"eighty":-2.049178,"marketCap":22680335},{"date":"2025-02-28","current":-2.238151,"twenty":-4.869408,"median":-2.636832,"eighty":-2.049178,"marketCap":20959758},{"date":"2025-03-07","current":-2.204746,"twenty":-4.859238,"median":-2.619088,"eighty":-2.043766,"marketCap":20646926},{"date":"2025-03-14","current":-2.021017,"twenty":-4.814317,"median":-2.611175,"eighty":-2.043766,"marketCap":18926349},{"date":"2025-03-21","current":-2.204746,"twenty":-4.762681,"median":-2.603257,"eighty":-2.043766,"marketCap":20646926},{"date":"2025-03-28","current":-2.021017,"twenty":-4.736,"median":-2.593961,"eighty":-2.037721,"marketCap":18926349},{"date":"2025-04-04","current":-1.904099,"twenty":-4.695977,"median":-2.574477,"eighty":-2.024878,"marketCap":17831436},{"date":"2025-04-11","current":-1.78718,"twenty":-4.601221,"median":-2.559576,"eighty":-2.021017,"marketCap":16736523},{"date":"2025-04-17","current":-2.338367,"twenty":-4.561033,"median":-2.554258,"eighty":-2.021017,"marketCap":21898255},{"date":"2025-04-25","current":-2.254854,"twenty":-4.395718,"median":-2.539152,"eighty":-2.021017,"marketCap":21116174},{"date":"2025-05-02","current":-2.221448,"twenty":-4.236599,"median":-2.517715,"eighty":-2.021017,"marketCap":20803342},{"date":"2025-05-09","current":-2.355069,"twenty":-4.022387,"median":-2.509122,"eighty":-2.021017,"marketCap":22054671},{"date":"2025-05-16","current":-2.188043,"twenty":-3.94774,"median":-2.501973,"eighty":-2.021017,"marketCap":20490510},{"date":"2025-05-23","current":-2.379913,"twenty":-3.876119,"median":-2.498632,"eighty":-2.021017,"marketCap":23149584},{"date":"2025-05-30","current":-2.524637,"twenty":-3.823943,"median":-2.498632,"eighty":-2.021017,"marketCap":24557329},{"date":"2025-06-06","current":-2.395993,"twenty":-3.78622,"median":-2.493989,"eighty":-2.021017,"marketCap":23306000},{"date":"2025-06-13","current":-2.494967,"twenty":-3.754515,"median":-2.493989,"eighty":-2.021017,"marketCap":24268720},{"date":"2025-06-20","current":-2.214076,"twenty":-3.676342,"median":-2.479073,"eighty":-2.020561,"marketCap":21536480},{"date":"2025-06-27","current":-2.032324,"twenty":-3.636238,"median":-2.464048,"eighty":-2.020561,"marketCap":19768560},{"date":"2025-07-03","current":-2.280168,"twenty":-3.554341,"median":-2.459464,"eighty":-2.020561,"marketCap":22179360},{"date":"2025-07-11","current":-2.329737,"twenty":-3.48487,"median":-2.44873,"eighty":-2.020561,"marketCap":22661520},{"date":"2025-07-18","current":-2.709765,"twenty":-3.426034,"median":-2.448382,"eighty":-2.020561,"marketCap":26358080},{"date":"2025-07-25","current":-2.825426,"twenty":-3.389044,"median":-2.448382,"eighty":-2.020561,"marketCap":27483120},{"date":"2025-08-01","current":-2.676719,"twenty":-3.365641,"median":-2.448382,"eighty":-2.020561,"marketCap":26036640},{"date":"2025-08-08","current":-2.610627,"twenty":-3.332199,"median":-2.448382,"eighty":-2.020561,"marketCap":25393760},{"date":"2025-08-15","current":-2.428875,"twenty":-3.310157,"median":-2.445165,"eighty":-2.020561,"marketCap":23625840},{"date":"2025-08-22","current":-2.263645,"twenty":-3.264565,"median":-2.436645,"eighty":-2.020561,"marketCap":22018640},{"date":"2025-08-29","current":-2.337999,"twenty":-3.264565,"median":-2.434612,"eighty":-2.020561,"marketCap":22741880},{"date":"2025-09-05","current":-2.271907,"twenty":-3.248873,"median":-2.421397,"eighty":-2.020104,"marketCap":22099000},{"date":"2025-09-12","current":-2.362783,"twenty":-3.247549,"median":-2.416566,"eighty":-2.020561,"marketCap":22982960},{"date":"2025-09-19","current":-2.34626,"twenty":-3.208752,"median":-2.407158,"eighty":-2.020561,"marketCap":22822240},{"date":"2025-09-26","current":-2.313214,"twenty":-3.208752,"median":-2.402267,"eighty":-2.020561,"marketCap":22500800},{"date":"2025-10-03","current":-2.63298,"twenty":-3.208752,"median":-2.395993,"eighty":-2.020561,"marketCap":24926330},{"date":"2025-10-10","current":-2.623774,"twenty":-3.208752,"median":-2.395993,"eighty":-2.020561,"marketCap":24839175},{"date":"2025-10-17","current":-2.669805,"twenty":-3.208752,"median":-2.395993,"eighty":-2.020561,"marketCap":25274950}],"updateTime":1760786922956},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NNVC\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2573944653","title":"NanoViricides Inc. Announces Date for Upcoming Annual Meeting of Stockholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2573944653","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573944653?lang=en_us&edition=fundamental","pubTime":"2025-10-08 18:03","pubTimestamp":1759917833,"startTime":"0","endTime":"0","summary":"NanoViricides Inc. has announced that it will hold its Annual Meeting of Stockholders on November 8, 2025, at the Hampton Inn & Suites Stamford in Stamford, Connecticut. During the meeting, shareholders will vote on several key proposals, including the re-election of Anil Diwan as a Class I director for a two-year term, an advisory vote on the compensation of the company's named executive officers, and the ratification and approval of EisnerAmper LLP as the company's independent registered public accounting firm for the 2026 fiscal year. Additionally, shareholders will consider a proposal to adjourn the meeting if necessary to solicit additional proxies, as well as any other business that may properly come before the meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as fi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251008:nNDLb366g8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4568","NNVC"],"gpt_icon":0},{"id":"2572568355","title":"NanoViricides Inc. Announces New Compensation Agreements, Extends President Dr. Anil Diwan’s Contract with $400,000 Salary and Equity Incentives","url":"https://stock-news.laohu8.com/highlight/detail?id=2572568355","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572568355?lang=en_us&edition=fundamental","pubTime":"2025-10-02 05:08","pubTimestamp":1759352929,"startTime":"0","endTime":"0","summary":"NanoViricides Inc. Announces New Compensation Agreements, Extends President Dr. Anil Diwan's Contract with $400,000 Salary and Equity Incentives. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 01, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251001:nNDLzgbgW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NNVC","BK4568","BK4139"],"gpt_icon":0},{"id":"2571652113","title":"Nanoviricides Q4 EPS $(0.13) Up From $(0.19) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2571652113","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571652113?lang=en_us&edition=fundamental","pubTime":"2025-09-30 05:55","pubTimestamp":1759182922,"startTime":"0","endTime":"0","summary":"Nanoviricides (AMEX:NNVC) reported quarterly losses of $(0.13) per share. This is a 31.58 percent increase over losses of $(0.19) per share from the same period last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/09/47931496/nanoviricides-q4-eps-0-13-up-from-0-19-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Nanoviricides Q4 EPS $(0.13) Up From $(0.19) YoY","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NNVC"],"gpt_icon":0},{"id":"2571534368","title":"NanoViricides Reports No Revenue for Fiscal Year Ended June 30, 2025; Net Loss Continues as R&D Expenses Rise by $112,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2571534368","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571534368?lang=en_us&edition=fundamental","pubTime":"2025-09-30 04:34","pubTimestamp":1759178057,"startTime":"0","endTime":"0","summary":"NanoViricides Inc. reported its financial results for the fiscal year ended June 30, 2025. The biopharmaceutical company reported no revenues for both the current and prior fiscal years. Net losses continued as the company has not commenced revenue-generating operations. Research and development expenses increased to $5.549 million for the year ended June 30, 2025, compared to $5.437 million for the year ended June 30, 2024. The increase of $0.112 million was mainly attributed to higher outside laboratory fees related to the preparation of Phase II clinical trial applications. NanoViricides stated its ongoing focus is on advancing drug candidates through preclinical studies and preparing for future clinical trials, with the goal of developing antiviral therapies using nanomedicine approaches. The company noted the potential for future developments in the antiviral field to impact its business plan and market opportunities.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nNDL5XcdJb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4568","NNVC"],"gpt_icon":0},{"id":"2566697128","title":"NanoViricides Inc. Announces Phase II Clinical Trial for Broad-Spectrum Antiviral NV-387 Targeting MPOX Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2566697128","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566697128?lang=en_us&edition=fundamental","pubTime":"2025-09-09 20:43","pubTimestamp":1757421812,"startTime":"0","endTime":"0","summary":"NanoViricides Inc., a clinical-stage company known for developing broad-spectrum antiviral drugs, has announced that it will be presenting updates on its drug pipeline, platform technologies, and new clinical developments at the Life Science Executive Partnering Congress in Boston on September 17, 2025. The presentation will be led by Anil R. Diwan, PhD, President and Executive Chairman of the company. Among the highlights is their most advanced candidate, NV-387, an ultra-broad-spectrum antiviral targeting multiple respiratory human pathogenic viruses. Additionally, the company will discuss its clinical-ready pan-herpesvirus drug candidate, NV-HHV-1, and its anti-HIV drug candidate, NV-HIV-1. These developments will be presented at the event, indicating that the results are yet to be formally disclosed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generate","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250909:nNDLGxgs8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","NNVC","BK4139"],"gpt_icon":0},{"id":"2560490741","title":"NanoViricides Inc. Advances NV-387 into Phase II Clinical Trials for Potential Cancer Resurgence and Viral Infection Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2560490741","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560490741?lang=en_us&edition=fundamental","pubTime":"2025-08-18 20:30","pubTimestamp":1755520228,"startTime":"0","endTime":"0","summary":"NanoViricides Inc. Advances NV-387 into Phase II Clinical Trials for Potential Cancer Resurgence and Viral Infection Treatment. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire  on August 18, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250818:nNDL3gvhN9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NNVC","BK4568","BK4139"],"gpt_icon":0},{"id":"2555104117","title":"NanoViricides Inc. Announces Promising Results for NV-387 in Combatting Global Measles Outbreaks, Seeks Accelerated FDA Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2555104117","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555104117?lang=en_us&edition=fundamental","pubTime":"2025-07-30 20:30","pubTimestamp":1753878621,"startTime":"0","endTime":"0","summary":"NanoViricides Inc. Announces Promising Results for NV-387 in Combatting Global Measles Outbreaks, Seeks Accelerated FDA Approval. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire  on July 30, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250730:nNDL9DmXPT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NNVC","BK4139","BK4568"],"gpt_icon":0},{"id":"2553017473","title":"NanoViricides Inc. Announces Breakthrough in Measles Treatment with Successful NV-387 Animal Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2553017473","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553017473?lang=en_us&edition=fundamental","pubTime":"2025-07-21 18:30","pubTimestamp":1753093823,"startTime":"0","endTime":"0","summary":"NanoViricides Inc., a clinical stage company specializing in broad-spectrum antivirals, has announced promising results from their recent animal study involving NV-387, a drug candidate aimed at treating Measles. The study utilized humanized mice to simulate Measles infection, as the virus does not naturally infect mice. NV-387 demonstrated a significant increase in survival rates, extending the average lifespan of infected animals from 7.4 days to 17 days, without any observed toxicity. The drug, designed to mimic cellular features essential for viral binding, showed a dose-dependent improvement in survival. These results indicate NV-387's potential as the first drug to effectively treat Measles, as global cases continue to rise.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250721:nNDL2xs61k:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4139","NNVC"],"gpt_icon":0},{"id":"2551284411","title":"NanoViricides Inc. Announces Phase II Clinical Trial for NV-387 to Combat MPox Epidemic","url":"https://stock-news.laohu8.com/highlight/detail?id=2551284411","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551284411?lang=en_us&edition=fundamental","pubTime":"2025-07-16 20:33","pubTimestamp":1752669220,"startTime":"0","endTime":"0","summary":"NanoViricides, Inc., a clinical-stage company specializing in broad-spectrum antiviral therapies, has announced the development of a clinical trial protocol for a Phase II study of NV-387, aimed at treating MPox disease in the African region. This randomized clinical trial will compare NV-387 treatment with the standard of care to evaluate the dosing regimen's safety, tolerability, and effectiveness against the MPXV virus. The trial comes in response to the ongoing MPox epidemic and the extension of the Public Health Emergency of International Concern  by the World Health Organization. No results from this impending study have been presented yet.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original c","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250716:nNDL50npL3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4568","NNVC"],"gpt_icon":0},{"id":"2551907464","title":"NanoViricides Inc. Nears Completion of Phase II Clinical Trial Design for Novel MPox Treatment NV-387","url":"https://stock-news.laohu8.com/highlight/detail?id=2551907464","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551907464?lang=en_us&edition=fundamental","pubTime":"2025-07-14 18:30","pubTimestamp":1752489033,"startTime":"0","endTime":"0","summary":"NanoViricides Inc., a publicly traded company focused on developing broad-spectrum antivirals, has announced that the design of its adaptive clinical trial protocol for treating MPox Virus Clade Ia and Ib infections with the novel drug NV-387 is nearing completion. The trial aims to gather data on safe and effective dosing regimens, the safety and tolerability of the drug, and its antiviral effectiveness. The adaptive, randomized, standard of care controlled trial will enroll approximately 80 patients and proceed in two parts. In the Phase IIa part, NV-387 will be compared with the standard of care over an initial six-day dosing period, with potential for extension based on patient outcomes. Currently, no drug is approved as effective for treating MPox. If NV-387 proves effective, it would be the first drug to demonstrate effectiveness against an orthopoxvirus in human clinical trials. Results of the trial are expected to provide crucial insights into the drug's safety and efficacy.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250714:nNDL6lCy3f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NNVC","BK4568","BK4139"],"gpt_icon":0},{"id":"2548300869","title":"NanoViricides Inc. Announces Phase II Clinical Trial for Broad-Spectrum Antiviral NV-387 Targeting MPox Infection","url":"https://stock-news.laohu8.com/highlight/detail?id=2548300869","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548300869?lang=en_us&edition=fundamental","pubTime":"2025-07-01 18:41","pubTimestamp":1751366491,"startTime":"0","endTime":"0","summary":"NanoViricides Inc., a publicly traded company specializing in the development of broad-spectrum antivirals, has announced the progression of its lead candidate, NV-387, into Phase II clinical trials for the treatment of MPox infection. This decision follows substantial efficacy data in animal studies for multiple indications, including RSV, Influenza, COVID, and Orthopoxviruses. The company has engaged a Clinical Research Organization to conduct the trial, with a site established in the Democratic Republic of Congo. The Clinical Trial Application is nearing completion, and manufacturing of the NV-387 substance is largely finished. The trial aims to expedite the company's pipeline towards revenue generation, with plans to extend NV-387's application to respiratory infections following the MPox trial. Results from this clinical study have yet to be presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to pro","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250701:nNDL4h0yG5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","NNVC","BK4139"],"gpt_icon":0},{"id":"2540050346","title":"NanoViricides Inc. Announces Imminent Animal Study for Promising Measles Drug Candidate NV-387","url":"https://stock-news.laohu8.com/highlight/detail?id=2540050346","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540050346?lang=en_us&edition=fundamental","pubTime":"2025-06-04 18:55","pubTimestamp":1749034520,"startTime":"0","endTime":"0","summary":"NanoViricides Inc., a clinical-stage company specializing in broad-spectrum antivirals, has announced the imminent commencement of an animal study for its Measles drug development program. The study will evaluate drug candidates in a lethal animal infection model, using specially modified mice that express the human CD150/SLAM protein, necessary for Measles virus entry into cells. The company is advancing its drug NV-387, which previously demonstrated efficacy against RSV in animals and may show similar effectiveness against Measles. NV-387 acts by mimicking cell features to bind and destroy viruses. The study aims to assess NV-387's potential for treating Measles, addressing a growing need as current Measles genotypes drift from existing vaccine strains. There is currently no approved drug for Measles, with Vitamin A and ribavirin being used in specific cases. Results from this study will inform the potential human application of NV-387.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nNDL47VQjN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4568","NNVC"],"gpt_icon":0},{"id":"2535239833","title":"NanoViricides Inc. Announces Phase II Clinical Trial for Broad-Spectrum Antiviral NV-387 to Combat MPox and Measles Outbreaks","url":"https://stock-news.laohu8.com/highlight/detail?id=2535239833","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535239833?lang=en_us&edition=fundamental","pubTime":"2025-05-16 18:31","pubTimestamp":1747391489,"startTime":"0","endTime":"0","summary":"NanoViricides Inc. Announces Phase II Clinical Trial for Broad-Spectrum Antiviral NV-387 to Combat MPox and Measles Outbreaks. NanoViricides Inc. has announced the advancement of its broad-spectrum antiviral drug candidate, NV-387, into Phase II clinical trials. The trials aim to evaluate the drug's effectiveness in treating MPox infections, a pressing medical need given the ongoing pandemic in Africa and spillover cases globally. NV-387 has previously demonstrated promising results in animal models against various viruses, including RSV, Influenza, and Poxviruses. Additionally, the company is preparing for Phase II trials targeting Viral Acute and Severe Acute Respiratory Infections. NanoViricides is also exploring NV-387's potential against Measles and Bird Flu. The company reported financial constraints but plans to secure funding through equity markets and partnerships to continue its development objectives.Disclaimer: This news brief was created by Public Technologies  using gener","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250516:nNDL4Rpq2n:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4139","NNVC"],"gpt_icon":0},{"id":"2535122806","title":"Nanoviricides Q3 GAAP EPS $(0.14) Up From $(0.16) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2535122806","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535122806?lang=en_us&edition=fundamental","pubTime":"2025-05-16 05:44","pubTimestamp":1747345464,"startTime":"0","endTime":"0","summary":"Nanoviricides (AMEX:NNVC) reported quarterly losses of $(0.14) per share. This is a 12.5 percent increase over losses of $(0.16) per share from the same period last year.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45456458/nanoviricides-q3-gaap-eps-0-14-up-from-0-16-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NNVC"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":14,"code":"91000000","status":"200"}]}}